<DOC>
	<DOCNO>NCT00232908</DOCNO>
	<brief_summary>This study evaluate patient quality life tolerability HAART ( highly active antiretroviral therapy ) regimen contain twice-daily subcutaneous injection Fuzeon clinically stable , treatment-experienced patient HIV-1 infection . All patient use 31-gauge thin-walled 8mm needle administer Fuzeon . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>QUALITE Study - A Study Fuzeon ( Enfuvirtide ) Treatment-Experienced Patients With Human Immunodeficiency Virus-1 ( HIV-1 ) Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<criteria>adult adolescent least 16 year age ; HIV1 infection ; clinically stable , treatmentexperienced ; evidence HIV1 replication despite ongoing antiretroviral therapy ; CD4 + count great 50 cells/mm3 . previous use Fuzeon and/or T1249 ; active , untreated opportunistic infection ; inability selfinject , unless reliable caregiver available inject .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>